Target type: biologicalprocess
Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of acetyl-CoA from pyruvate. [GOC:dph, GOC:tb]
The regulation of acetyl-CoA biosynthesis from pyruvate is a complex process involving multiple enzymes, metabolic pathways, and regulatory mechanisms. Acetyl-CoA is a central molecule in metabolism, serving as a key building block for various cellular processes, including fatty acid synthesis, cholesterol synthesis, and the citric acid cycle.
**Pyruvate Dehydrogenase Complex (PDC):**
* The first step in acetyl-CoA synthesis from pyruvate is catalyzed by the pyruvate dehydrogenase complex (PDC), a multienzyme complex located in the mitochondrial matrix.
* PDC converts pyruvate to acetyl-CoA through a series of enzymatic reactions, requiring the cofactors thiamine pyrophosphate (TPP), lipoic acid, coenzyme A (CoA), flavin adenine dinucleotide (FAD), and nicotinamide adenine dinucleotide (NAD+).
**Regulation of PDC Activity:**
* **Product Inhibition:** Acetyl-CoA, NADH, and ATP, the products of the PDC reaction, act as allosteric inhibitors of the enzyme. This negative feedback mechanism prevents overproduction of acetyl-CoA when cellular energy levels are high.
* **Phosphorylation by Pyruvate Dehydrogenase Kinase:** The activity of PDC is also regulated by phosphorylation. Pyruvate dehydrogenase kinase (PDK) phosphorylates specific serine residues on the E1 subunit of PDC, leading to inactivation of the enzyme.
* **Dephosphorylation by Pyruvate Dehydrogenase Phosphatase:** Pyruvate dehydrogenase phosphatase (PDP) dephosphorylates the E1 subunit, reactivating the enzyme.
* **Hormonal Regulation:** Insulin, a hormone that promotes glucose uptake and utilization, activates PDP, thereby increasing PDC activity. Conversely, glucagon, a hormone that stimulates glucose production, activates PDK, inhibiting PDC activity.
**Other Regulatory Mechanisms:**
* **Citrate:** Citrate, an intermediate of the citric acid cycle, is a potent allosteric inhibitor of PDC. This feedback mechanism prevents excessive flux through the citric acid cycle when energy demands are low.
* **Calcium:** Calcium ions have been shown to activate PDC in certain tissues, such as skeletal muscle.
**Metabolic Regulation:**
* The regulation of acetyl-CoA synthesis from pyruvate is intricately linked to other metabolic pathways. For example, the availability of pyruvate, derived from glucose metabolism, directly influences the rate of acetyl-CoA production.
* The cellular energy status also plays a crucial role. When ATP levels are high, PDC activity is inhibited to conserve energy. Conversely, when ATP levels are low, PDC is activated to produce more acetyl-CoA for energy production.
**Summary:**
The regulation of acetyl-CoA biosynthesis from pyruvate is a complex and tightly controlled process involving various enzymes, regulatory mechanisms, and metabolic pathways. This fine-tuned control ensures that the production of this essential molecule is balanced with the cell's energy needs and metabolic demands.'
"
Protein | Definition | Taxonomy |
---|---|---|
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial | A [pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q16654] | Homo sapiens (human) |
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial | A [pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q15120] | Homo sapiens (human) |
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial | A [pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q15119] | Homo sapiens (human) |
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial | A [pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q15118] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
nu6102 | NU6102: structure in first source | ||
dichloroacetic acid | monocarboxylic acid; organochlorine compound | astringent; marine metabolite | |
dibenzothiazyl disulfide | dibenzothiazol-2-yl disulfide : An organic disulfide resulting from the formal oxidative coupling of the thiol groups of two molecules of 1,3-benzothiazole-2-thiol. It is used as an accelerator in the rubber industry. dibenzothiazyl disulfide: vulcanizing accelerant | benzothiazoles; organic disulfide | allergen |
nandrolone | nandrolone : A 3-oxo Delta(4)-steroid that is estr-4-en-3-one substituted by a beta-hydroxy group at position 17. Nandrolone: C18 steroid with androgenic and anabolic properties. It is generally prepared from alkyl ethers of ESTRADIOL to resemble TESTOSTERONE but less one carbon at the 19 position. | 17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; anabolic androgenic steroid | human metabolite |
abietic acid | abietic acid : An abietane diterpenoid that is abieta-7,13-diene substituted by a carboxy group at position 18. | abietane diterpenoid; monocarboxylic acid | plant metabolite |
staurosporine | indolocarbazole alkaloid; organic heterooctacyclic compound | apoptosis inducer; bacterial metabolite; EC 2.7.11.13 (protein kinase C) inhibitor; geroprotector | |
dehydroabietylamine | dehydroabietylamine: has antimalarial activity; structure in first source | diterpenoid | |
birb 796 | aromatic ether; morpholines; naphthalenes; pyrazoles; ureas | EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; immunomodulator | |
zeneca zd 6169 | Zeneca ZD 6169: an ATP-sensitive potassium channel opener; structure given in first source | ||
2-oxindole | 2-oxindole: RN given refers to parent cpd; structure indolin-2-one : An indolinone carrying an oxo group at position 2. | gamma-lactam; indolinone | |
6-bromoindirubin-3'-oxime | 6-bromoindirubin-3'-oxime : A member of the class of biindoles that is indirubin substituted at position 6 by a bromo group and in which the keto group at position 3' has undergone condensation with hydroxylamine to form the corresponding oxime. 6-bromoindirubin-3'-oxime: structure in first source | ||
sodium dichloroacetate | CPC 211: for intravenous use in patients with closed head injuries and stroke patients; no further information available 12/99 | ||
monorden | monorden: inhibits HSP90 Heat-Shock Proteins, DNA topoisomerase VI and human Topoisomerase II | cyclic ketone; enone; epoxide; macrolide antibiotic; monochlorobenzenes; phenols | antifungal agent; metabolite; tyrosine kinase inhibitor |
norethisterone-3-oxime | |||
tofacitinib | tofacitinib : A pyrrolopyrimidine that is pyrrolo[2,3-d]pyrimidine substituted at position 4 by an N-methyl,N-(1-cyanoacetyl-4-methylpiperidin-3-yl)amino moiety. Used as its citrate salt to treat moderately to severely active rheumatoid arthritis. | N-acylpiperidine; nitrile; pyrrolopyrimidine; tertiary amino compound | antirheumatic drug; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor |
ly2090314 | LY-2090314 : A member of the class of diazepinoindoles that is 1,2,3,4-tetrahydro[1,4]diazepino[6,7,1-hi]indole substituted by piperidin-1-ylcarbonyl, 4-(imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl and fluoro groups at position 2, 7 and 9, respectively. It is a potent ATP-competitive inhibitor of glycogen synthase kinase-3 (GSK-3) with IC50 values of 1.5 nM and 0.9 nM for GSK-3alpha and GSK-3beta. The drug is in clinical development for the treatment of advanced/metastatic cancer. | diazepinoindole; imidazopyridine; maleimides; monofluorobenzenes; piperidinecarboxamide; ureas | antineoplastic agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; Wnt signalling activator |
bx795 | BX795: structure in first source | ureas | |
sotrastaurin | sotrastaurin : A member of the class of maleimides that is maleimide which is substituted at position 3 by an indol-3-yl group and at position 4 by a quinazolin-4-yl group, which in turn is substituted at position 2 by a 4-methylpiperazin-1-yl group. It is a potent and selective inhibitor of protein kinase C and has been investigated as an immunosuppresant in renal transplant patients. sotrastaurin: a potent protein kinase C-selective inhibitor; structure in first source | indoles; maleimides; N-alkylpiperazine; N-arylpiperazine; quinazolines | anticoronaviral agent; EC 2.7.11.13 (protein kinase C) inhibitor; immunosuppressive agent |
l 783277 | |||
at 7519 | 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide : A member of the class of pryrazoles that is 4-amino-1H-pyrazole-3-carboxylic acid in which the primary amino group has been acylated by a 2,6-dichlorobenzoyl group and in which the carboxylic acid has been converted into a carboxamide by formal condensation with the primary amino group of 4-aminopiperidine. | dichlorobenzene; piperidines; pyrazoles; secondary carboxamide | antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor |
gw 2580 | 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine: a cFMS kinase inhibitor; structure in first source | ||
4-[2-(2-chloro-4-fluoroanilino)-5-methyl-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide | Vx-11e: ERK1-2 inhibitor | aromatic amide; heteroarene | |
pha 767491 | PHA 767491: a Cdc7 inhibitor; structure in first source | pyrrolopyridine | |
azd 7545 | AZD 7545: an anilide tertiary carbinol; a pyruvate dehydrogenase kinase 2 inhibitor AZD7545 : A sulfone that is benzene substituted by [4-(dimethylcarbamoyl)phenyl]sulfonyl, chloro and [(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]amino groups at positions 1, 3 and 4, respectively. It is a potent and non-ATP-competitive inhibitor of pyruvate dehydrogenase kinase 2 (PDHK2) with IC50 of 6.4 nM and exhibits glucose-lowering activity. Also inhibits PDHK1 at higher levels (IC50 = 36.8 nM). | benzamides; monochlorobenzenes; organofluorine compound; secondary carboxamide; sulfone; tertiary alcohol; tertiary carboxamide | EC 2.7.11.2 - [pyruvate dehydrogenase (acetyl-transferring)] kinase inhibitor; hypoglycemic agent |
mrt67307 | MRT67307: IKK (IκB(inhibitor of NF-κB (nuclear factor κB)) kinase) family inhibitor; structure in first source | aromatic amine | |
pha 793887 | piperidinecarboxamide | ||
gsk 2334470 | GSK 2334470: a PDK1 inhibitor; structure in first source | indazoles | |
nms p937 | NMS P937: a polo-like kinase 1 inhibitor; structure in first source | ||
ver-246608 | VER-246608: inhibits pyruvate dehydrogenase kinase; structure in first source | ||
at 9283 | |||
nms-e973 | NMS-E973: structure in first source |